Core Insights - BioAge Labs, Inc. has reported positive interim Phase 1 data for BGE-102, a novel NLRP3 inhibitor, indicating potential best-in-class reductions in inflammatory biomarkers related to cardiovascular risk [1][2] - The company plans to initiate a Phase 2a proof-of-concept trial for BGE-102 in cardiovascular risk in the first half of 2026 and has expanded its indication into ophthalmology with a trial for diabetic macular edema planned for mid-2026 [1][5] Business Highlights - The Phase 1 trial of BGE-102 demonstrated well-tolerated results with significant pharmacokinetics supporting once-daily dosing, achieving 90-98% suppression of IL-1β and cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above [5] - In the first MAD cohort, BGE-102 120 mg once daily achieved an 86% median reduction in hsCRP, with 93% of participants reaching levels below 2 mg/L, indicating reduced cardiovascular risk [5] - The company completed an upsized follow-on public offering generating total gross proceeds of approximately $132.3 million, which will support its expanding clinical programs [1][8] Financial Results - For the year ended December 31, 2025, collaboration revenue was $9.0 million, a significant increase from no revenue in 2024, attributed to a multi-year research collaboration with Novartis [10] - Research and development expenses rose to approximately $73.9 million in 2025 from $59.0 million in 2024, primarily due to increased costs related to various programs including BGE-102 [11] - The net loss for the year was $80.6 million, or $2.24 per share, compared to a net loss of $71.1 million, or $6.63 per share, in 2024 [15]
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025